Accelerating R&D to Commercialization by Leveraging Predictive Biomarkers & Clinical Diagnostics Evidence for Best Patient Outcomes in Target Populations

The 11th World Clinical Biomarkers & CDx Summit returned in 2021 as the only end-to-end industry-led meeting diving deep into the science of transitioning biomarkers to the clinic, their clinical validation and later commercialization with a CDx.

With over half of drugs approved by the FDA now supported by a biomarker and as new CDx collaborations are announced on an almost weekly basis, demand for diagnostic tools enabling earlier, more precise, therapeutic interventions is at an all time high. 650+ key stakeholders from across biomarker, translational, clinical, regulatory and commercial functions joined to tackle end-to-end challenges and deliver game-changing drug-Dx products to market.

Across 2 days of comprehensive content65+ global expert speakers shared fresh data paired with inspiring stories from innovative partnership collaborations to help you overcome your most pressing challenges and accelerate curative medicine for heterogeneous patient populations.

With 3 tracks addressing the entire lifecycle of biomarker-driven drug development, exploring biomarkers and Dx movement within bioanalytical analysis, AI/ML application, data sharing and the regulatory and payer landscape and covering immune-oncology, neurodegenerative, metabolic, autoimmune and rare indications, attendees gained a diverse picture of today’s expanding personalized medicine ecosystem.

This is your unmissable event, bringing you the tools, insights and techniques to design a clinically robust biomarker and commercially competitive CDx!

Your Plenary Speakers

Gathered by the aim of getting the best option to the right patient as quickly and efficiently as possible, unite with the 1000+ of your precision medicine peers to explore precision medicine opportunity to treat diverse populations, end-to-end CDx development case studies, latest diagnostic interventions reaching the market and biopharma’s efforts to maximise the utility of data.

Christopher Conn

Director, Companion Diagnostics Strategy Lead


Danielle Murphy

Director, Translational Oncology


Kashyap Patel


Community Oncology

Kaye Foster

Senior Advisor & Executive Coach

The Boston Consulting Group (BCG)

Moving Biomarkers Towards the Clinic Speakers

Support your early biomarker discovery and development through robust analytical validation and effectively validate and translate assays to make the clinical transition. Meet leaders challenging complex disease heterogeneity across immune-oncology, metabolic, autoimmune and neurodegenerative disease with NGS, organoid modelling, multi-omics and comprehensive data collection.

Andrea Stevens

Global CoDx Market Access Director

Janssen Inc.

Brian Baker

Senior Director, Regulatory Affairs (CDx)

Regeneron Pharmaceuticals

Chowdary Dondapati

Executive Director, Head of CDx Marketing (US)

Bayer Oncology

Eugean Jiwanmall

Senior Research Analyst for Medical Policy & Technology Evaluation

Independence Blue Cross

Katherine Block

Director, Biomarker Sciences

Sangamo Therapeutics

Clinical Biomarker & Assay Development

Draw actionable insights from clinical data to establish an effective trial strategy and inform treatment decisions making an impact in target populations. Showcasing data from small molecules, T-cell therapies, bispecific antibodies and neoantigen studies, and featuring the latest on liquid biopsy and genomic analysis, determine your clinical cut-offs with confidence.

Alessandra Cesano

Chief Medical Officer

ESSA Pharma

David Portman

Chief Executive Officer, Chief Medical Officer

Sermonix Pharmaceuticals

Ellie Corigliano

Head of CDx Cell & Gene Therapies Oncology


Jennifer Dacpano- Komansky

Director, Global Regulatory Affairs, Medical Devices


Markus Zettl

Senior Director of Immuno–Oncology

Pieris Pharmaceuticals GmbH

Drug-Dx Co-Development

Develop, identify and validate the technologies you need to obtain optimal results from your trials then establish effective internal and external stakeholder collaboration to expedite drug-Dx commercialization whilst optimizing reimbursement. Apply expert practical knowledge to navigate the fast-growing CDx market delving into case studies across oncology in addition to emerging gene therapy and rare disease, and gain a picture of the real-world-evidence and patient perspectives broadening assay adoption.

Arunthi Thiagalingam

Director, Pharmacology/ Translational Medicine

Spectrum Pharmaceuticals

Chris Whelan

Associate Director & Head of Translational Genetics


Joshua Xu

Branch Chief, National Center for Toxicological Research

US Food & Drug Administration

Michael Fossel

President & Founder


Featuring exclusive updates on the latest technologies, tools and techniques innovating biomarker-driven drug development, meet our 2021 event partners: